{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:01:23Z","timestamp":1765040483648},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T00:00:00Z","timestamp":1410998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/jhh.2014.79","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T09:21:12Z","timestamp":1411032072000},"page":"229-235","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension"],"prefix":"10.1038","volume":"29","author":[{"given":"J","family":"Dingemanse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Otasevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Shakeri-Nejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Klainman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Putnikovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kracker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Zimlichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"BFjhh201479_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206\u20131252.","journal-title":"Hypertension"},{"key":"BFjhh201479_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1524-6175.2007.08145.x","volume":"10","author":"KA Jamerson","year":"2008","unstructured":"Jamerson KA, Basile J . Prompt aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich ) 2008; 10: 40\u201348.","journal-title":"J Clin Hypertens (Greenwich )"},{"key":"BFjhh201479_CR3","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1592\/phco.27.12.1677","volume":"27","author":"TC Trujillo","year":"2007","unstructured":"Trujillo TC, Dobesh PP . Traditional management of chronic stable angina. Pharmacotherapy 2007; 27: 1677\u20131692.","journal-title":"Pharmacotherapy"},{"key":"BFjhh201479_CR4","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527\u20131535.","journal-title":"Lancet"},{"key":"BFjhh201479_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","volume":"13","author":"WJ Elliott","year":"2011","unstructured":"Elliott WJ, Ram CV . Calcium channel blockers. J Clin Hypertens (Greenwich) 2011; 13: 687\u2013689.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFjhh201479_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0002-9149(97)00271-3","volume":"79","author":"L Michalewicz","year":"1997","unstructured":"Michalewicz L, Messerli FH . Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol 1997; 79: 39\u201346.","journal-title":"Am J Cardiol"},{"key":"BFjhh201479_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.clinthera.2009.08.010","volume":"31","author":"K Makarounas-Kirchmann","year":"2009","unstructured":"Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P . Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 2009; 31: 1652\u20131663.","journal-title":"Clin Ther"},{"key":"BFjhh201479_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1254\/jphs.FMJ05002X5","volume":"99","author":"H Tanaka","year":"2005","unstructured":"Tanaka H, Shigenobu K . Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development. J Pharmacol Sci 2005; 99: 214\u2013220.","journal-title":"J Pharmacol Sci"},{"key":"BFjhh201479_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/S0149-2918(97)80011-2","volume":"19","author":"FE Karch","year":"1997","unstructured":"Karch FE, Pordy R, Benz JR, Carr A, Lunde NM, Marbury T et al. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group. Clin Ther 1997; 19: 1368\u20131378.","journal-title":"Clin Ther"},{"key":"BFjhh201479_CR10","doi-asserted-by":"publisher","first-page":"27C","DOI":"10.1016\/S0002-9149(97)00567-5","volume":"80","author":"BM Massie","year":"1997","unstructured":"Massie BM, Lacourciere Y, Viskoper R, Woittiez A, Kobrin I . Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists. Am J Cardiol 1997; 80: 27C\u201333C.","journal-title":"Am J Cardiol"},{"key":"BFjhh201479_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4070\/kcj.2010.40.10.514","volume":"40","author":"IY Oh","year":"2010","unstructured":"Oh IY, Seo MK, Lee HY, Kim SG, Kim KS, Kim WH et al. Beneficial effect of Efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild-to-moderate essential hypertension. Korean Circ J 2010; 40: 514\u2013519.","journal-title":"Korean Circ J"},{"key":"BFjhh201479_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.jhh.1000453","volume":"11","author":"RJ Viskoper","year":"1997","unstructured":"Viskoper RJ, Bernink PJ, Schelling A, Ribeiro AB, Kantola IM, Wilkins MR et al. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group. J Hum Hypertens 1997; 11: 387\u2013393.","journal-title":"J Hum Hypertens"},{"key":"BFjhh201479_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/FJC.0000000000000030","volume":"63","author":"MS Mueller","year":"2014","unstructured":"Mueller MS, Shakeri-Nejad K, Gutierrez MM, Krause A, T\u00e4ubel J, Sanderson B et al. Tolerability and pharmacokinetics of ACT-280778, a novel non-dihydropyridine dual L\/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs. J Cardiovasc Pharmacol 2014; 63: 120\u2013131.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFjhh201479_CR14","unstructured":"Pfizer Inc. NORVASC\u00ae (amlodipine besylate): Highlights of Prescribing Information 2013, Available at http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=562."},{"key":"BFjhh201479_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00126097-200112000-00008","volume":"6","author":"MG Myers","year":"2001","unstructured":"Myers MG, Lipicky RJ . Assessment of antihypertensive activity in the regulatory setting. Blood Press Monit 2001; 6: 309\u2013312.","journal-title":"Blood Press Monit"},{"key":"BFjhh201479_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2165\/00003495-199141030-00009","volume":"41","author":"D Murdoch","year":"1991","unstructured":"Murdoch D, Heel RC . Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991; 41: 478\u2013505.","journal-title":"Drugs"},{"key":"BFjhh201479_CR17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S0149-2918(97)80048-3","volume":"19","author":"N Bittar","year":"1997","unstructured":"Bittar N . Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group. Clin Ther 1997; 19: 954\u2013962.","journal-title":"Clin Ther"},{"key":"BFjhh201479_CR18","first-page":"403","volume":"2","author":"RL Talbert","year":"1983","unstructured":"Talbert RL, Bussey HI . Update on calcium-channel blocking agents. Clin Pharm 1983; 2: 403\u2013416.","journal-title":"Clin Pharm"},{"key":"BFjhh201479_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jacc.2004.03.057","volume":"44","author":"D Zeltser","year":"2004","unstructured":"Zeltser D, Justo D, Halkin A, Rosso R, Ish-Shalom M, Hochenberg M et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 2004; 44: 105\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201479_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S0895-7061(02)03000-5","volume":"15","author":"G Leonetti","year":"2002","unstructured":"Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A . Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932\u2013940.","journal-title":"Am J Hypertens"},{"key":"BFjhh201479_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/jhh.2008.161","volume":"23","author":"T Fujiwara","year":"2009","unstructured":"Fujiwara T, Ii Y, Hatsuzawa J, Murase H, Watanabe T, Murakami M et al. The Phase III double-blind, parallel-group controlled study of amlodipine 10\u2009mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5\u2009mg once daily. J Hum Hypertens 2009; 23: 521\u2013529.","journal-title":"J Hum Hypertens"},{"key":"BFjhh201479_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.clinthera.2008.09.008","volume":"30","author":"RD Miranda","year":"2008","unstructured":"Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine\/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine\/ramipril (ATAR) study. Clin Ther 2008; 30: 1618\u20131628.","journal-title":"Clin Ther"},{"key":"BFjhh201479_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000095950","volume":"108","author":"RS DePaula","year":"2007","unstructured":"DePaula RS, Antelmi I, Vincenzi MA, Andr\u00e9 CD, Artes R, Grupi CJ et al. Cardiac arrhythmias and atrioventricular block in a cohort of asymptomatic individuals without heart disease. Cardiology 2007; 108: 111\u2013116.","journal-title":"Cardiology"},{"key":"BFjhh201479_CR24","first-page":"e6","volume":"127","author":"AS Go","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics2013 update: a report from the American Heart Association. Circulation 2013; 127: e6\u2013e245.","journal-title":"Circulation"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201479","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:10:06Z","timestamp":1647547806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFjhh201479"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2014.79","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]},"assertion":[{"value":"14 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was sponsored by Actelion Pharmaceuticals Ltd. Dr Dingemanse, Dr Shakeri-Nejad, Dr Kracker and Dr Mueller were employees and stockholders of Actelion Pharmaceuticals Ltd at the time the study was conducted. Dr Otasevic and Dr Zimlichman received honoraria from Actelion Pharmaceuticals Ltd for assistance with clinical trials, and Dr Klainman and Dr Putnikovic have no conflict of interest relevant to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}